Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

NCT02706288
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

NCT00588094
View directory record Official record
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 14, 2026, 2:12 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Energy Drinks on Cardiovascular Endpoints

NCT07212803
View directory record Official record
Conditions
Healthy Volunteers, Safety After Oral Intake
Interventions
Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule, Placebo Drink + Placebo Capsule, Energy Drink B, Control Product + Taurine, Control Product + Caffeine + Taurine, Lower Dose Energy Drink A
Dietary Supplement · Drug · Other
Lead sponsor
University of the Pacific
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

NCT05021341
View directory record Official record
Conditions
Glycemia
Interventions
Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT00408005
View directory record Official record
Conditions
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions
Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
1,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
191
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

5-HTP and Creatine for Depression

NCT04395183
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-Hydroxytryptophan 100 MG, Creatine monohydrate, placebo matched to 5-HTP, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 40 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

NCT04674306
View directory record Official record
Conditions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions
α-lactalbumin vaccine, Zymosan
Biological
Lead sponsor
George T. Budd
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 2:12 AM EDT
Not yet recruiting Phase 3 Interventional

Fezolinetant and Vascular Health and Brain Health

NCT07606664
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
Placebo, Fezolinetant
Drug
Lead sponsor
Rebecca Thurston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sympathetic Activation in Obesity

NCT04946552
View directory record Official record
Conditions
Obesity, Healthy
Interventions
PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Diagnostic Test · Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Fish Oil and HMB Supplementation in COPD

NCT03796455
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Capsule + Powder supplementation, stable tracer infusion
Dietary Supplement · Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

NCT00423514
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
filgrastim, clofarabine, melphalan, mycophenolate mofetil, tacrolimus, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 54 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Effect of Whole Blueberry Powder Consumption on Depression in a Central Louisiana Population

NCT04398784
View directory record Official record
Conditions
Depression, Depression, Anxiety, Inflammation
Interventions
Freeze Dried Blueberry Powder - 71717, USHBC Blueberry Placebo Formula #114
Dietary Supplement
Lead sponsor
Louisiana State University, Baton Rouge
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Cottonport, Louisiana • Marksville, Louisiana
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol/glycopyrrolate, indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 14, 2026, 2:12 AM EDT
Recruiting Phase 2 Interventional

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

NCT02605421
View directory record Official record
Conditions
Neuroblastoma
Interventions
Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 14, 2026, 2:12 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

NCT05095311
View directory record Official record
Conditions
Exercise-induced Arterial Hypoxemia
Interventions
Cetirizine HCl, Placebo
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 14, 2026, 2:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Age-associated Arterial Dysfunction, Western Diet, and Aerobic Exercise: Role of the Gut Microbiome

NCT03334201
View directory record Official record
Conditions
Aging
Interventions
Western Diet, Non-Western Diet
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01349972
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Diet Composition on Performance, Expenditure, Blood Lipids, and Appetite Hormones in Highly Trained Cyclists

NCT04097171
View directory record Official record
Conditions
Endurance Cycling Performance
Interventions
Diet
Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00003401
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 14, 2026, 2:12 AM EDT